Medley Therapeutics

Medley Therapeutics is a biotechnology company launched by Flagship Pioneering in 2024 to pioneer the field of extracellular matrix (ECM) medicine. The company's proprietary platform is designed to decode the 'matrisome,' the complex network of proteins that provides structural and biochemical support to tissues. By understanding how the ECM regulates cell behavior and tissue health, Medley aims to develop a new class of therapies that can restore tissue function and reverse disease. The company's initial focus is on chronic conditions driven by ECM dysfunction, including fibrosis and inflammatory diseases. Medley's approach shifts the therapeutic focus from individual cells to the broader tissue environment, offering a novel strategy for treating hard-to-manage diseases.